We are live on ! Find out more
CYTO

Altamira Therapeutics Ltd
CYTO

Delisted

CYTO was delisted on the 19th of December, 2024.

Back to rankings

10 hedge funds and large institutions have $37.1M invested in Altamira Therapeutics Ltd in 2016 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more funds holding

Funds holding: 8 → 10 (+2)

18% more capital invested

Capital invested by funds: $31.4M → $37.1M (+$5.65M)

Holders
10
Holders Change
+2
Holders Change %
+25%
% of All Funds
0.27%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
1
Reduced
–
Closed
–
Calls
$4K
Puts
–
Net Calls
+$4K
Net Calls Change
+$5K

Top Buyers

Rank Fund Capital Flow
1
FO
FT Options
Illinois
+$299K
2
RSCM
Rock Springs Capital Management
Maryland
+$299K

Top Sellers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
-$90K
2
ZIM
Zacks Investment Management
Illinois
-$86K
3
VKH
Virtu KCG Holdings
New York
-$46K
4
AIG
American International Group
New York
-$13K
5
JP Morgan Chase
JP Morgan Chase
New York
-$5K

CYTO Hedge Fund Activity: Q2 2016 in Review

10 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Altamira Therapeutics Ltd (CYTO) for Q2 2016, worth a combined $37.1M — up 18% from $31.4M a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new CYTO positions and 0 closed out — a net gain of 2 holders — while 1 added to existing stakes and 0 trimmed.

The largest buyer was FT Options, opening a new position worth an estimated $299K. The largest seller was Goldman Sachs, cutting an estimated $90K.

  • 10 institutional investors held Altamira Therapeutics Ltd (CYTO) as of Q2 2016, up from 8 in Q1 2016.
  • Funds reported $37.1M of Altamira Therapeutics Ltd stock for Q2 2016, up 18% quarter-over-quarter.
  • 2 funds opened new Altamira Therapeutics Ltd positions in Q2 2016 and 0 closed out, a net change of +2 holders.
  • The largest Altamira Therapeutics Ltd buyer in Q2 2016 was FT Options, an estimated $299K added.
  • The largest Altamira Therapeutics Ltd seller in Q2 2016 was Goldman Sachs, an estimated $90K sold.

Based on aggregated 13F filings for Q2 2016.